chartexchange

Pfizer's Launched and Acquired Drugs Grew 32% in Q3 — and 3 Other Reasons to Buy the Stock Before 2027

The Motley Fool | Nov 20, 2026 5:15 PM EST

Pfizer (NYSE:PFE) faces a large patent cliff, and investors worry it won't be able to offset the revenue it loses as older drugs face generic competition. That's a problem, but the drugmaker is aware of it and is making important strides in its efforts to address the issue. The big story, however, is that this issue is pretty normal for a drug company. In fact, revenue from recently launched and acquired drugs rose 32% in the third quarter of 2026. That shows the pharmaceutical giant's efforts are bearing fruit. But there's more reason to be excited, including the company's strong balance sheet, its large dividend, and management's commitment to continue paying that dividend. Here's what you need to know. Image source: Getty Images. Continue reading

Read original article